News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim GmbH Release: VERxVE Study Demonstrates Efficacy and Safety of 400mg Once Daily Nevirapine (Viramune(R)) Extended Release (NVP XR) Formulation



7/22/2010 9:14:48 AM

INGELHEIM, Germany & VIENNA--(BUSINESS WIRE)--Results from the VERxVE study presented today at the 18th International AIDS Society (IAS) conference in Vienna, Austria, show that once daily nevirapine extended release (XR) formulation (400mg QD) Viramune® is non-inferior to the currently used twice daily immediate release (200mg BID) Viramune® (IR) through 48 weeks.

Read at BioSpace.com


comments powered by Disqus
   
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES